로딩 중…
지수 로딩 중…
Ocular Therapeutix, Inc.
OCUL· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$8.40+2.82%
2026-08-03
Financials
Valuation Metrics
Ocular Therapeutix, Inc.'s Market Cap is $1.84B. At end of 2025 it was $2.71B. Ranked #2114 of 3,112 in US market (top 68%), #818 of 1,445 on NASDAQ (top 57%), #146 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 54%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.84B | US#2,114/3,112 Sec#146/269 |
| Revenue | $52M | US#2,857/3,112 Sec#154/269 |
| Net Income | $-290M | US—/3,112 Sec—/269 |
| Total Assets | $733M | US#2,585/3,112 Sec#121/269 |
| Net Assets | $582M | US#2,140/3,112 Sec#97/269 |
| Value | ||
| P/B | 3.16x | US#1,731/3,112 Sec#91/269 |
| P/S | 35.34x | US#2,862/3,112 Sec#162/269 |
| FCF Yield | -13.10% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -49.95% | US#2,741/3,112 Sec#174/269 |
| ROA | -39.66% | US#2,925/3,112 Sec#191/269 |
| Op. Margin | -575.42% | US#2,901/3,112 Sec#165/269 |
| Revenue Growth | 0.81% | US#2,160/3,112 Sec#123/269 |
| Financial Health | ||
| Debt Ratio | 25.96% | US#283/3,112 Sec#92/269 |
| Total Debt | $79M | US#2,442/3,112 Sec#129/269 |
| FCF | $-241M | US#2,758/3,112 Sec#229/269 |
| Cash | $667M | US#892/3,112 Sec#41/269 |
| Current Ratio | 14.81x | US#163/3,112 Sec#52/269 |
| Performance | ||
| 1Y Return | -29.53% | US#2,782/3,112 Sec#228/269 |
| 1M Return | -12.86% | US#2,736/3,112 Sec#190/269 |
| From 52W High | -48.91% | US#2,759/3,112 Sec#214/269 |
| 1Y MDD | -57.29% | US#2,663/3,112 Sec#207/269 |
| Trading | ||
| Volume | 3,273,093 shares | US#578/3,112 Sec#46/269 |
| Trading Value | $27M | US#1,788/3,112 Sec#127/269 |
| Per Share | ||
| EPS | $-1.19 | US—/3,112 Sec—/269 |
| BPS | $2.94 | US#2,425/3,112 Sec#160/269 |